Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma

BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway reactivation through receptor tyrosine kinase (RTK)/SRC-family kinase (SFK) si...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Cell
Autors principals: Girotti, Maria Romina, Lopes, Filipa, Preece, Natasha, Niculescu-Duvaz, Dan, Zambon, Alfonso, Davies, Lawrence, Whittaker, Steven, Saturno, Grazia, Viros, Amaya, Pedersen, Malin, Suijkerbuijk, Bart M.J.M., Menard, Delphine, McLeary, Robert, Johnson, Louise, Fish, Laura, Ejiama, Sarah, Sanchez-Laorden, Berta, Hohloch, Juliane, Carragher, Neil, Macleod, Kenneth, Ashton, Garry, Marusiak, Anna A., Fusi, Alberto, Brognard, John, Frame, Margaret, Lorigan, Paul, Marais, Richard, Springer, Caroline
Format: Artigo
Idioma:Inglês
Publicat: Cell Press 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297292/
https://ncbi.nlm.nih.gov/pubmed/25500121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2014.11.006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars